TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01913964
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: (sugar pill)
Study: NCT03529253
Drug: Alirocumab 75 MG/ML [Praluent]+ Rosuvastatin 10mg/daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab group receive Alirocumab75mg/2week subcutaneous injection plus Rosuvastatin10mg/daily by oral for 9 months.
Study: NCT03529253
Drug: Rosuvastatin calcium10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin10mg/daily by oral for 9 months.
Study: NCT03666442
Drug: XELOX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xelox chemotherapy,that oxaliplatin 130mg/m2 d1,capecitabine 1000mg/m2 twice daily d1-14,every 3 weeks
Study: NCT01076153
Drug: Clarithromycin (Klacid® MR)
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Klacid MR 500mg (clarithromycin)
Study: NCT00401921
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg, 1 capsule PO BID starting 36 hours prior to surgery. 2 capsules the morning of surgery
Study: NCT00401921
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule PO BID starting 36 hours prior to surgery. 2 capsules the morning of surgery.
Study: NCT03970655
Drug: Bupivacaine or Ropivacaine with epinephrine plus dexamethasone - Group 1
Normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 will receive 4 ml of 0.5% Bupivacaine or Ropivacaine with epinephrine in the LEFT pterygopalatine fossa
Study: NCT03970655
Drug: Bupivacaine or Ropivacaine with epinephrine plus dexamethasone - Group 2
Normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 will receive 4 ml of 0.5% Bupivacaine or Ropivacaine with epinephrine in the RIGHT pterygopalatine fossa
Study: NCT01085643
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24mcg placebo capsule taken once
Study: NCT02384187
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 0.3 ml/kg of a placebo solution identical in taste, shape and color to the study medication two hours before the induction of anesthesia.
Study: NCT00715403
Drug: BIBF 1120
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03462173
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo Capsule
Study: NCT04028362
Drug: Neuromuscular Blocking Agents
Normalized name: NEUROMUSCULAR BLOCKING AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient who will receive neuromuscular blockade will be follow during their ICU lenght stay.
Study: NCT01316406
Drug: ATH008
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subject will be incorporated in the study and randomised to ATH008 cream 3% or 8% or ATH008 cream placebo
Study: NCT03854942
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablet daily
Study: NCT00457730
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects are randomized to either Duloxetine or Placebo
Study: NCT02150928
Drug: Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Enrolled patients will receive asparaginase Erwinia chrysanthemi 25,000 IU/m2 administered intramuscularly (IM) on a Monday/Wednesday/Friday schedule (all dosing regimens will start on a Monday)~* All patients will receive at least 1 course (2 weeks) of treatment with asparaginase Erwinia chrysanthemi (1 course=6 doses), and a maximum number of courses needed to complete their remaining asparaginase therapy (up to 15 courses)~* Eligible patients may not begin treatment with asparaginase Erwinia chrysanthemi until their serum asparaginase activity level is below the assay detectable limit
Study: NCT00201643
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Course of Placebo (NS)
Study: NCT02187159
Drug: DS-5565
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-5565 15 mg tablet for oral administration
Study: NCT02187159
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet (matching DS5565) for oral administration
Study: NCT02187159
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule (matching pregabalin) for oral administration
Study: NCT02593721
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The active comparator group received an oral Ibuprofen treatment. The starting dose was of 400 mg/day and it was increased to a maximum of 1200 mg/day divided in 3 oral intakes every 8 hours depending on patient tolerance.The intervention was applied during a period of 6 weeks.
Study: NCT01514253
Drug: Glucose 25%
Normalized name: glucose 25% oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml glucose 25%, once
Study: NCT01406717
Drug: SPIL1033
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mcg twice daily for the first 4 weeks and 10 mcg twice daily for the remaining 20 weeks. To be self-administered twice daily.
Study: NCT01406717
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mcg twice daily for the first 4 weeks and 10 mcg twice daily for the remaining 20 weeks. To be self-administered twice daily.
Study: NCT01417143
Drug: TKI258 (Dovitinib):
Approvals — FDA: no, EMA: no, PMDA: no
Description: TKI258 (Dovitinib): 500 mg daily po medication with 5 days on/2 days off schedule. TKI258 (Dovitinib) will be provided by Norvatis for the study purpose. One cycle consists of 4 weeks
Study: NCT03552705
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day course of oral placebo and intravenous saline during ACL reconstruction surgery
Study: NCT03513016
Drug: UBX0101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drug intra-articular injection
Study: NCT02031523
Drug: Sanjie analgesic capsule
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, four each time, 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle.or follow the doctor's advice.
Study: NCT02031523
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral，four each time, 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle. Or Follow the doctor's advice.
Study: NCT03308669
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01083342
Drug: MTX, MVD, VIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX: Methotrexate,Leucovorin MVD: Methotrexate,Vincristine,Dexamethasone VIA: VP-16 (Etoposide),Ifosfamide,Mesna, Cytarabine (ara-C)
Study: NCT01366664
Drug: Treatment sequence 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Period 1 (stable dose of terazosin \[2, 5, or 10 mg\] + dapoxetine 60 mg administered orally once daily for 5 days) followed up to 14 days later by Treatment Period 2 (stable dose of terazosin \[2, 5, or 10 mg\] + placebo administered orally once daily for 5 days)
Study: NCT00311363
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, orally, once daily for 12 weeks following single blind 24-week phase
Study: NCT01093846
Drug: AIN457
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg every 4 weeks
Study: NCT00492518
Drug: Theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00492518
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01093846
Drug: AIN457
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg every 2 weeks
Study: NCT01093846
Drug: Placebo AIN457
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to AIN457
Study: NCT03532711
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: chemotherapy treated patients
Study: NCT00486005
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02904759
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02620813
Drug: Tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will apply 0.5% tretinoin cream nightly to their face for a total of 12 weeks.
Study: NCT00978523
Drug: AR-12: (2-Amino-N-[4-[5-(2 phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] phenyl]-acetamide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, dose-escalation
Study: NCT00863915
Drug: Atlace® 10 mg capsules, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products sprinkled on one tablespoonful of applesauce
Study: NCT01856738
Drug: Placebo (for rivastigmine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule. Dose 3,0 - 6,0 mg BID
Study: NCT05108766
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to tildrakizumab administered SC
Study: NCT02261467
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline) injected into the protocol-specified areas on Day 1.
Study: NCT00699049
Drug: Alpha blocker
Normalized name: ALPHA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00699049
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00234845
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00958503
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched tablets without active ingredient
Study: NCT01353859
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10-25 mg orally weekly
Study: NCT04343287
Drug: BRM421
Approvals — FDA: no, EMA: no, PMDA: no
Description: The active control with BRM421 solution
Study: NCT04343287
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The vehicle solution
Study: NCT03909529
Drug: Spironolactone 25 mg/ 5 mL S/F Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention is for study of drug drug interaction of digoxin when administered with spironolactone oral suspension
Study: NCT02233218
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02587988
Drug: HGP0904
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02587988
Drug: Placebo (for HCP1302)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02587988
Drug: Placebo (for HGP0904)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01141556
Drug: Selenase
Normalized name: selenite
Approvals — FDA: no, EMA: no, PMDA: no
Description: After enrollment, patients will be prospectively randomized into two groups: a placebo group without selenium and a group receiving a loading dose of selenium 4000 μg intraoperatively,followed by a daily dosage of 1000 μg until leaving the ICU (longest supplementation 13 days).
Study: NCT02751541
Drug: Sunscreen Sport Spray (BAY987519)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 μl/cm\*2 or 0.05 gm/cm\*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each). After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.24 hours later, the set of patches covering the product are removed. Three (3) μl/ cm2 or 0.003 gm/cm\*2 of the test product is reapplied to the test site, air dried for 5 to 15 minutes for volatilization and then the test site is exposed to UVA radiation.(Formulation number - RB#Y51-002)
Study: NCT00700427
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral delivery of matching placebo
Study: NCT01917721
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The interventional arm of the study will receive doxycycline 4.4 mg/kg/day for 21 days besides receiveing standard care: IVIG and/or Remicade.
Study: NCT01917721
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical care and placebo will be provided to the comparative arm of the study administering IVIG and/or Remicade, but not doxycycline.
Study: NCT03040167
Drug: Bupivacaine with epinephrine
Normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group
Study: NCT03040167
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group
Study: NCT02172144
Drug: Placebo matching BI 1744 CL
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01669434
Drug: ACEI continuation
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: These chronic medications will be taken without interruption preoperatively.
Study: NCT01669434
Drug: ACEI omission
Normalized name: Veneno de Abeja Aceite de Vibora
Approvals — FDA: no, EMA: no, PMDA: no
Description: Although taken chronically by patients in this intervention, the final preoperative dose of these medications will be omitted, whether it was scheduled for the morning of surgery or the day prior.
Study: NCT00669370
Drug: docetaxel and capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: biweekly docetaxel iv (50 mg/m2) on day 1 and 15 and capecitabine po 1250 mg/m2 x 2/day days 1-7 and 15-21, treatment cycle consisting of 21 days
Study: NCT00825123
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose powder
Study: NCT00044291
Drug: aromatase inhibition
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01851941
Drug: mFOLFOX6 (folinic acid, 5-fluorouracil, and oxaliplatin )
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified FOLFOX6 regimen consists of oxaliplatin 100 mg/m2 and FA 100 mg/m2 given as a 2 hour intravenous infusion, followed by 5-FU 2.4 g/m2 given as a continuous infusion over 46 hour, which is repeated every 2 weeks. Patients receive 4 cycles of neoadjuvant modified FOLFOX6 followed by curative radical surgery with D2 dissection and 4 cycles of adjuvant modified FOLFOX6.
Study: NCT03577249
Drug: Dialysis Solutions
Normalized name: dialysis solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution A: 3mmol/L of acetate anion; Solution B: 1mmol/L of citrate anion
Study: NCT01811732
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01944657
Drug: Standard Medication Monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: These medications could include bupropion (Wellbutrin and others), citalopram (Celexa and others), Clomipramine (Ananfranil and others), duloxetine (Cymbalta), escitalopram (Lexapro and others), fluoxetine (Prozac and others), fluvoxamine (Luvox and others), imipramine (Tofranil and others), mirtazapine (Remeron and others), nortriptylatine (Pamelor, Aventyl, and others), paroxetine (Paxil, Pexeva, and others), phenelzine (Nardil), sertraline (Zoloft and others), tranylcypromine (Parnate and others), venlafaxine (Effexor and others).
Study: NCT00814138
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg weekly for 2 weeks and then increase to 15mg for 2 weeks and then 20mg weekly until the end of the study
Study: NCT04126304
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: If the diagnosis is common cold, acute bronchitis or post-infection cough ，treated with non-macrolides when the mycoplasma colloidal gold test is negative, treated with azithromycin when colloidal gold test is positive.
Study: NCT04126304
Drug: non-macrolides antibiotics
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: If the diagnosis is community-acquired pneumonia with negative mycoplasma antibody-granule agglutination, non-macrolides are used for treatment
Study: NCT01253096
Drug: Intratumoral injections of L19IL2
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with intratumoral injections of L19IL2 1-3 x weekly. The maximum cumulative dose per week is 20 MioIU. Treatment duration is up to 20 weeks.
Study: NCT02104661
Drug: Oxcarbazepine
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxcarbazepine 150mg tablet, over encapsulated and back-filled with Microcrystalline Cellulose/Magnesium Stearate 1%.
Study: NCT02104661
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in a matched capsule containing Microcrystalline Cellulose/Magnesium Stearate 1%.
Study: NCT02603198
Drug: mepivacaine chloridrato epinephrine
Normalized name: epinephrine / mepivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: local anesthesia for tooth removal
Study: NCT00774475
Drug: doubled therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: clopidogrel 150 mg/day
Study: NCT02976519
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily
Study: NCT00483652
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (sugar pill)
Study: NCT01427335
Drug: calcium
Normalized name: Calcium
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion of 10 % calcium gluconate 10 mL in 200 mL of physiologic saline on the day of ovum pickup, day 1,day 2, and day 3 after ovum pickup were administered in study group.~Intravenous infusion was performed within 30 minutes
Study: NCT01427335
Drug: 0.9 % saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 % saline intravenous infusion
Study: NCT01626066
Drug: LUM015
Approvals — FDA: no, EMA: no, PMDA: no
Description: LUM015 assigned dose given once by IV push
Study: NCT00005645
Drug: ILX-295501
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02689843
Drug: Cyproterone compound + Spironolactone
Normalized name: cyproterone
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone compound (Cyproterone Acetate 2mg-Ethinyl estradiol 35mcg) 1 tablet daily + Spironolactone 50 mg twice daily
Study: NCT03173417
Drug: fludarabine and cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two days before cell infusion,all patients will be treated with fludarabine and cyclophosphamide for 3 days
Study: NCT03322293
Drug: Aminolevulinic Acid Topical 20% Topical Solution
Normalized name: aminolevulinic acid topical 20% topical solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDT involves the topical application of aminolevulinic acid (ALA), or one of its derivatives, as a photosensitizing agent. Subjects will receive ALA in all treatment arms (A, B, and C).
Study: NCT02659943
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg/m\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3
Study: NCT05715385
Drug: eye drop bromfenac 0.09%
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily e/d bromfenac 0.09% for 6 weeks
Study: NCT05715385
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation group. No intervention done. Only eye drop carboxymethyl cellulose 0.5% to be instilled thrice a day for 6 weeks.
Study: NCT03583567
Drug: 0.9% Normal Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will receive normal saline as placebo.
Study: NCT00942305
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects received their first dose of study drug within 30 (+5) days post-transplant and were treated through Week 13 post-transplant.~Matching placebo administered for each cohort.
Study: NCT02342470
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug : Placebo
Study: NCT02342470
Drug: PMK-S005 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug : PMK-S005 1 (50mg)
Study: NCT02342470
Drug: PMK-S005 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug : PMK-S005 2 (100mg)
Study: NCT02342470
Drug: PMK-S005 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug : PMK-S005 3 (150mg)
Study: NCT04144101
Drug: Etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 60 mg QD Oral
Study: NCT03441113
Drug: MMB
Normalized name: Methylmethionine sulfonium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet(s) administered orally once daily
Study: NCT01449721
Drug: Intravenous fluid
Normalized name: Intravenous fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Sodium chloride intravenous fluid
Study: NCT01260857
Drug: Aldazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldazide 25 mg OD
Study: NCT00334672
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00334672
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00334672
Drug: therapeutic hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05635942
Drug: optimized quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Association of amoxicillin 3 g/day + Esomeprazole, nitroimidazole and clarithromycin for 14 days
Study: NCT05635942
Drug: standard quadruple therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Association of amoxicillin 2 g/day + Esomeprazole, nitroimidazole and clarithromycin for 14 days
Study: NCT01464840
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg intravenous infused over 1 hour
Study: NCT03212716
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of diltiazem
Study: NCT02617615
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: It will be identical in appearance and similar in weight to the MB-110 hard-gel capsule.
Study: NCT03415516
Drug: Single Bond2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adhesive systems
Study: NCT01723072
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to omalizumab
Study: NCT02782312
Drug: ICS+LABA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seretide is inhaled for one year